Cardio Diagnostics Holdings In

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercialize a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company is headquartered in Chicago, IL.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded in 2007, and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc today announced that it is sponsoring Becker's Hospital Review 13th Annual Meeting.

Cardio Diagnostics Holdings, Inc Sponsors Becker's Hospital Review 13th Annual Meeting

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc today announced that it has entered into a securities purchase agreement with YA II PN, Ltd.

Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced Dr. Damon Broyles, MD has joined Cardio Diagnostics as a strategic advisor.

Cardio Diagnostics Holdings, Inc Welcomes Dr. Damon Broyles, MD, as Strategic Advisor for Precision Cardiovascular Medicine Strategy

Cardio Diagnostics (NASDAQ: CDIO ) stock is on the move Thursday after the company announced an expansion to its IP portfolio. That comes after China's Patent Office issued a Notice of Allowance to the University of Iowa Research Foundation for its “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease” patent.

Why Is Cardio Diagnostics (CDIO) Stock Up 5% Today?

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China's Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”

Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application

Helbiz

Lucira Health

Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks: The Importance of Liquidity and Volume

What could possibly cause Cardio Diagnostics (NASDAQ: CDIO ) to more than double in a single day? Without a doubt, today's action in CDIO stock is due to the company's announcement of a new product.

Why Is Cardio Diagnostics (CDIO) Stock Up 150% Today?

CHICAGO--(BUSINESS WIRE)--PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease.

Cardio Diagnostics Holdings Inc Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc today announced its newest coronary heart disease test, PrecisionCHD™.

Cardio Diagnostics Holdings Inc to Debut PrecisionCHD™ at the American College of Cardiology's 72nd Annual Scientific Session

Blue Apron

Arqit Quantum Inc

Are penny stocks better than blue chips? Here's why The post Penny Stocks Vs.

Penny Stocks Vs. Blue Chips, Which Should You Trade?

CHICAGO--( BUSINESS WIRE )--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing Sanctuary Clinic, a leading medical practice serving health-forward consumers in Idaho, today announced the availability of Cardio Diagnostics' Epi+Gen CHD test in Idaho.

Healing Sanctuary Clinic Partners With Cardio Diagnostics Holdings Inc to Offer the Epi+Gen CHD Test in their Medical Practice in Idaho

CHICAGO--( BUSINESS WIRE )--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023.

Cardio Diagnostics Holdings Inc to Attend 41st Annual JP Morgan Healthcare Conference

HOUSTON--( BUSINESS WIRE )--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Houston Concierge Medicine, a leading medical practice serving executives and health-forward consumers in Houston, today announced the use of Cardio Diagnostics' Epi+Gen CHD test. This test, which combines epigenetics, genetics, high-throughput computing, and AI to identify those at risk for coronary heart disease, is now available to Houston Concierge Medicine patients as part of their Executive Health Program.

Houston Concierge Medicine Partners With Cardio Diagnostics to Offer the Epi+Gen CHD Test in Their Executive Health Program

CHICAGO--( BUSINESS WIRE )--Cardio D iagnostics Holdings Inc (Nasdaq: CDIO) today announced it would be presenting at the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022, at the New York Athletic Club in New York City.

Cardio Diagnostics to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CHICAGO--( BUSINESS WIRE )--Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring the Illinois Association of Medicaid Health Plans' (IAMHP) Annual Conference entitled “Bringing Equity into Focus.” The conference is taking place this week, November 14-16, 2022, at the Hyatt Lodge Hotel in Oakbrook. As part of Cardio Diagnostics' sponsorship, Meesha Dogan, PhD, CEO, is presenting on How to Optimize Health Equity Initiatives at the Population Health Level.

Cardio Diagnostics Holdings Inc Sponsors the Illinois Association of Medicaid Health Plan's Annual Conference

CHICAGO--( BUSINESS WIRE )--Meesha Dogan, PhD, the CEO of Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.

Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker's Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.

Cardio Diagnostics Holdings Inc Sponsors Becker's Hospital Review 11th Annual Meeting - The CEO + CFO Roundtable

Cardio Diagnostics (NASDAQ: CDIO ) stock is on the move Friday as investors push shares higher following its public debut yesterday. Let's get into everything investors need to know about Cardio Diagnostics, as well as the details of how it went public.

CDIO Stock: 7 Things to Know as Cardio Diagnostics Starts Trading

Mana Capital Acquisition Corp

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. ("Cardio" or the “Company”), a pioneering precision cardiovascular medicine company at the intersection of epigenetics and artificial intelligence whose products enable improved prevention, early detection and treatment of cardiovascular disease, today announced the completion of its business combination (the “Business Combination”) with Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (“Mana Capital”), a publicly tra

News for Cardio Diagnostics Holdings In Stock (CDIO)